Identification of a minimal region of loss on chromosome 6q27 associated with poor survival of high-risk neuroblastoma patients

References

• Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2015;62:225–256. PMID:25435121. doi:10.1016/j.pcl.2014.09.015.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–11. PMID:23702928. doi:10.1038/nrc3526.
   PubMed Web of Science ®Google Scholar
• Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–1510. PMID:18349403. doi:10.1200/JCO.2007.12.3349.
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, et al. The challenge of defining “ultra-high-risk” neuroblastoma. Pediatr Blood Cancer. 2019;16:e27556. PMID:30479064. doi:10.1002/pbc.27556.
   Google Scholar
• Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–583. PMID:21298742. doi:10.1002/pbc.22693.
   PubMed Web of Science ®Google Scholar
• Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–297. PMID:19047291. doi:10.1200/JCO.2008.16.6785.
   PubMed Web of Science ®Google Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211. PMID:20558371. doi:10.1056/NEJMra0804577.
   PubMed Web of Science ®Google Scholar
• Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–1961. PMID:10379019. doi:10.1056/NEJM199906243402504.
   PubMed Web of Science ®Google Scholar
• Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–2253. PMID:16306521. doi:10.1056/NEJMoa052399.
   PubMed Web of Science ®Google Scholar
• Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225–230. PMID:8531999. doi:10.1056/NEJM199601253340404.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, et L. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. J Am Med Assoc. 2012;307:1062–1071. PMID:22416102. doi:10.1001/jama.2012.228.
   PubMed Web of Science ®Google Scholar
• Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27:1026–1033. PMID:19171713. doi:10.1200/JCO.2008.16.0630.
   PubMed Web of Science ®Google Scholar
• Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372:195–209. PMID:29572647. doi:10.1007/s00441-018-2821-2.
   PubMed Web of Science ®Google Scholar
• Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49–63. PMID:25386934. doi:10.1146/annurev-med-011514-023121.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007;46:936–949. PMID:17647283. doi:10.1002/gcc.20477.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45:279–284. PMID:23334666. doi:10.1038/ng.2529.
   PubMed Web of Science ®Google Scholar
• Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483:589–593. PMID:22367537. doi:10.1038/nature10910.
   PubMed Web of Science ®Google Scholar
• Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45:12–17. PMID:23202128. doi:10.1038/ng.2493.
   PubMed Web of Science ®Google Scholar
• Ognibene M, Pagnan G, Marimpietri D, Cangelosi D, Cilli M, Benedetti MC, Boldrini R, Garaventa A, Frassoni F, Eva A, et al. CHL1 gene acts as a tumor suppressor in human neuroblastoma. Oncotarget. 2018;9:25903–25921. PMID:29899830. doi:10.18632/oncotarget.25403.
   PubMedGoogle Scholar
• Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, et al. Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst. 2018;110:1084–1093. PMID:29514301. doi:10.1093/jnci/djy022.
   PubMedGoogle Scholar
• Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Łastowska M, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005;23:2280–2299. PMID:15800319. doi:10.1200/JCO.2005.06.104.
   PubMed Web of Science ®Google Scholar
• Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, et al. The DNA sequence and analysis of human chromosome 6. Nature. 2003;425:805–811. PMID:14574404. doi:10.1038/nature02055.
   PubMed Web of Science ®Google Scholar
• Trubia M, Sessa L, Taramelli R. Mammalian Rh/T2/Sglycoprotein ribonuclease family genes: cloning of a human member located in a region of chromosome 6 (6q27) frequently deleted in human malignancies. Genomics. 1997;42:342–344. PMID:9192857. doi:10.1006/geno.1997.4679.
   PubMed Web of Science ®Google Scholar
• Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AER, Charnock FML, Beck S, Dunham I, Mungall AJ, et al. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene. 2007;26:683–700. PMID:16878154. doi:10.1038/sj.onc.1209827.
   PubMed Web of Science ®Google Scholar
• Mikolajka A, Yan X, Popowicz GM, Smialowski P, Nigg EA, Holak TA. Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization. Mol Biol. 2006;359:863–875. PMID:16690081. doi:10.1016/j.jmb.2006.03.070.
   Web of Science ®Google Scholar
• Guasch G, Delaval B, Arnoulet C, Xie MJ, Xerri L, Sainty D, Birnbaum D, Pébusque MJ. FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. Blood. 2004;103:309–312. PMID:12969958. doi:10.1182/blood-2003-05-1690.
   PubMed Web of Science ®Google Scholar
• Morandi F, Barco S, Stigliani S, Croce M, Persico L, Lagazio C, Scuderi F, Belli ML, Montera M, Cangemi G, et al. Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget. 2017;8:53194–53209. PMID:28881804. doi:10.18632/oncotarget.18285.
   PubMedGoogle Scholar
• Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, et al. Revisions to the International neuroblastoma response criteria: A consensus statement from the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2017;35:2580–2587. PMID:28471719. doi:10.1200/JCO.2016.72.0177.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, et al. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010;28:3516–3524. PMID:20567002. doi:10.1200/JCO.2009.27.3524.
   PubMed Web of Science ®Google Scholar
• Parodi S, Pistorio A, Erminio G, Ognibene M, Morini M, Garaventa A, Gigliotti AR, Haupt R, Frassoni F, Pezzolo A. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile. Pediatr Blood Cancer. 2019;66:e27635. PMID:30688024. doi:10.1002/pbc.27635.
   PubMed Web of Science ®Google Scholar